Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial

He Zhang P. Menasché Jia-Hao Fan Ling Gao Han-Qing Luo Yun-Xing Xue Xiyu Zhu Qian Wang Cheng-Wu Li Yong-Sheng Xu Alex J. Zhang Jia-Xian Wang Dong-Jin Wang

Aug 2026 · Nature Medicine · Vol 32, pp. 3331 - 3338 · 0 citations · 51 references

Medicine

TL;DR

Primary efficacy analyses indicated that cell transplantation provided significantly greater improvements in 6-min walk distance, global myocardial perfusion and relative wall thickening and relative wall thickening compared with coronary artery bypass grafting alone.

DOI PubMed Semantic Scholar

View source

Similar papers

Open access Aug 2026

Efficacy of multi-layered human iPS cell-derived cardiovascular cell sheets in a pacing-induced canine dilated cardiomyopathy model

IHJ-301 significantly improved multiple parameters of cardiac function, providing preclinical evidence that IHJ-301 could offer a promising therapeutic option for DCM.

Yu Shimoyama, Kenji Kakuta, Kiho Araki et al. · Stem cell research & therape... · 0 citations

#protein folding Open access Aug 2026

Human iPSC-cardiomyocyte-aggregate cell therapy in non-human primates and correlation of heart recovery with contractile and electrophysiological cardiomyocyte properties

This study demonstrates the successful production and injection of human induced pluripotent stem cell cardiomyocyte aggregates into infarcted cynomolgus monkey hearts, resulting in substantial, structured human grafts three months after cell transplantation, and uncoupling of cardiomyocyte production from transplantat...

I. Gruh, Andreas Martens, S. Cebotari et al. · Nature Communications · 0 citations

Open access Sep 2026

Poor survival after myocardial infarction in immune deficient NXG B2m mice is alleviated by transplantation of induced pluripotent stem cell derived cardiomyocytes (iPSC-CM) formulated as spheres, but not single cells

The data suggest that iPSC-vCM sphere formulation may offer some benefits for intracardiac delivery as compared with single cell formulated iPSC-vCMs, and thus remains a promising candidate for reestablishing the lost CMs after MI in the future.

Anne Kathrine Søgaard Terp, D. Ellman, Sabrina Bech Mathiesen et al. · bioRxiv · 0 citations

2026

Induced Pluripotent Stem Cells and 3D Bioprinting Strategies for Cardiac Regeneration After Myocardial Infarction

This study evaluates the role of iPSCs and different biofabrication methods, such as bioprinting, used to create ventricular constructs and cardiac patches that support injured regions of the heart post-MI.

N. Shenoy · American Journal of Student... · 0 citations

Review Open access Aug 2026

Clinical landscape of human pluripotent stem cell-derived cardiomyocyte therapy.

The pathophysiological rationale for cell-based therapy in heart failure with reduced ejection fraction is summarized, and the preclinical foundations of distinct hPSC-derived product formats are examined, including cell suspensions, epicardial sheets, engineered heart muscle, and cardiac spheroids, each with distinct...

Byron W H Mui, E. Neofytou, Joseph C. Wu · Cell Reports Medicine · 0 citations

Open access Jul 2026

Extracellular vesicle secretome from mesenchymal stromal cells prevents post-ischemic heart failure by targeting cardiac fibrosis.

A clinically approved PDGFRβ-targeted PET-imaging platform for longitudinal assessment of fibrotic activity in STEMI patients and preliminary observations suggest that myofibroblast activation persists for up to 2 months after STEMI in selected patients establish a translational therapeutic-diagnostic framework for ind...

Karl-Henrik Grinnemo, Ken Braesch-Andersen, Johan O. Wedin et al. · Cell Stem Cell · 1 citation